Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Faculty:
Joyce F. Liu, MD, MPH
Associate Chief and Director of Clinical Research
Division of Gynecologic Oncology, Dept. of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Advisory/Consulting/Speaker’s Fees for: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Genmab, GlaxoSmithKline, Loxo@Lilly, Regeneron Therapeutics, Revolution Medicine, SystImmune, Zentalis Pharmaceuticals
Kathleen N. Moore, MD, MS
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at OU Health
University of Oklahoma, Health Science Center
Oklahoma City, OK
Dr. Moore has no relevant relationships to disclose.
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Wilma Guerra has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify the critical unmet therapeutic needs in the management of platinum-resistant ovarian cancer that create an opportunity for biomarker-directed treatment strategies
- Describe the mechanism of action of CDH6-targeted antibody-drug conjugates in ovarian cancer
- Interpret emerging clinical evidence and safety profiles from early-phase trials of CDH6-directed therapies in platinum-resistant ovarian cancer
- Discuss the potential integration of CDH6-targeted agents into future treatment strategies for platinum-resistant ovarian cancer
Target Audience
This activity has been designed to meet the educational needs of oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with ovarian cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.50 contact hour(s)/0.05 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-133-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 11/14/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from Merck Sharpe & Dohme LLC & Daiichi Sankyo Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
